Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06251076 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Plan Development for Giving Teclistamab in the Outpatient Setting

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 10, 2025 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Apr 15, 2025 to Jun 15, 2026 · Study sites: 0 to 1 · Completion date: Sep 4, 2025 to Oct 2026 · 1 morev4 Show 4 more changesShow less
    • Primary completion date: Apr 15, 2025 to Jun 15, 2026
    • Study sites: 0 to 1
    • Completion date: Sep 4, 2025 to Oct 2026
    • Start date changed from estimate of Oct 15, 2024 to Nov 19, 2024
  2. Start date: Apr 15, 2024 to Oct 15, 2024v3
  3. Start date: Mar 4, 2024 to Apr 15, 2024 Primary endpoints revised (2) · Primary completion date: Mar 4, 2025 to Apr 15, 2025 · Eligibility criteria expanded, about 33 words · 1 morev2 Show 4 more changesShow less
    • Primary endpoints revised (2)
    • Primary completion date: Mar 4, 2025 to Apr 15, 2025
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoint revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab.
Trial Details
NCT Number NCT06251076
Lead Sponsor University Health Network, Toronto
Collaborators: Janssen Inc.
Conditions Multiple Myeloma, Relapsed Cancer, Refractory Cancer
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov